[CAS NO. 1033040-23-1] TPO agonist 1
PRODUCTS SPECIFICATIONS [1033040-23-1]
DESCRIPTION [1033040-23-1]
Overview
| MDL | MFCD30343847 |
|---|---|
| Molecular Weight | 466.49 |
| Molecular Formula | C25H22N8O2 |
| SMILES | O=C(N(C1=CC=C(C)C(C)=C1)N=C/2C)C2=N\NC3=C(O)C(C4=CC=CC(C5=NN=NN5)=C4)=CC=C3 |
Summary
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia [1] .
IC50 & Target
TPO receptor [1]
In Vivo
The thrombopoietin (TPO) receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes, and can increases platelet counts, decrease bleeding events and reduce the need for adjunctive or rescue treatments. The TPO receptor agonists are well-tolerated, though uncertainty remains regarding the risk of thromboembolism and bone marrow fibrosis [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 36 mg/mL ( 77.17 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1437 mL | 10.7183 mL | 21.4367 mL |
| 5 mM | 0.4287 mL | 2.1437 mL | 4.2873 mL |
| 10 mM | 0.2144 mL | 1.0718 mL | 2.1437 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2 mg/mL (4.29 mM); Suspended solution; Need ultrasonic
References